ClinicalTrials.gg
CompletedNCT04003103Updated Jul 18, 2025Results posted

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

A Phase 2 interventional study of Islatravir and Placebo in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection

Read the detailed description

This study is ongoing for collection of safety follow-up of infants born to mothers participating in the study. The present results are based on the Week 68 interim analysis.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in general good health with acceptable laboratory values at screening
  • Is confirmed -uninfected based on negative HIV-1/HIV-2 test result before randomization
  • Has low risk of HIV infection, within 12 months prior to screening visit or the rescreening visit (if applicable)
  • Use consistent with local regulations
  • Female is not pregnant or breastfeeding, and is not a woman of (WOCBP)
  • A WOCBP is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; or has a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has an active diagnosis of hepatitis due to any cause
  • Has a history of ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapies from 30 days prior to Day

    1 through the duration of the study.

  • Is currently participating in or has participated in an interventional clinical study with an compound or device within 30 days prior to Day1 through the duration of the study.
  • Has previously been randomized in a study and received islatravir (MK-8591).
  • Female is expecting to conceive or donate eggs at any time during the study
  • Has (using Fridericia correction) >450 msec (for males) or >460 msec (for females) or deemed clinically abnormal by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Islatravir 60 mg

    60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks

    Drug: Islatravir · Drug: Placebo

  • Experimental
    Islatravir 120 mg

    120 mg islatravir administered once monthly, orally in capsule form for 24 weeks

    Drug: Islatravir

  • Placebo comparator
    Placebo

    Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks

    Drug: Placebo

Interventions

  • Islatravir 30 mg capsules taken by mouth.

    Also known as: MK-8591

  • DrugPlacebo

    Placebo capsules taken by mouth.

06

What researchers measure

Primary outcomes

  1. Number of Participants With ≥1 Adverse Event (AE) Through Week 36

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 36 weeks

  2. Number of Participants Discontinuing From Study Therapy Due to AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 20 weeks

  3. Number of Participants Discontinuing From Study Therapy Due to ≥1 Drug-related AE

    A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study therapy.

    Time frame: Up to 20 weeks

  4. Number of Participants With ≥1 Drug-related AE Through Week 36

    A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.

    Time frame: Up to 36 weeks

  5. Number of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36

    An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.

    Time frame: Up to 36 weeks

  6. Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 36

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').

    Time frame: Up to 36 weeks

  7. Number of Participants With ≥1 Drug-related SAE Through Week 36

    An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.

    Time frame: Up to 36 weeks

  8. Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 36

    A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).

    Time frame: Up to 36 weeks

  9. Number of Participants With an AE Resulting in Death Through Week 36

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 36 weeks

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Dosing to 672 Hours Postdose (AUC0-672) of Plasma ISL

    The AUC0-672 of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

    Time frame: Day 1 and Day 140: predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.

  2. Maximum Plasma Concentration (Cmax) of ISL

    The Cmax of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

    Time frame: Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.

  3. Trough Plasma Concentration (Ctrough) of ISL

    The plasma Ctrough of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

    Time frame: Day 1 and Week 20: predose and 30-min postdose. Day 2: 24 hours post Day 1 dose. Weeks 1, 2, 3, 21, 22, 23 and 24: any time during the study visit. Weeks 4, 8, 12 and 16: predose.

  4. Apparent Plasma Terminal Half-life (t1/2) of ISL

    The plasma t1/2 of ISL after dosing on Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

    Time frame: Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.

  5. Number of Participants With ≥1 AE Through Week 24

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 24 weeks

  6. Number of Participants With ≥1 Drug-related AE Through Week 24

    A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.

    Time frame: Up to 24 weeks

  7. Number of Participants With ≥1 SAE Through Week 24

    An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.

    Time frame: Up to 24 weeks

  8. Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 24

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').

    Time frame: Up to 24 weeks

  9. Number of Participants With ≥1 Drug-related SAE Through Week 24

    An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.

    Time frame: Up to 24 weeks

  10. Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 24

    A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).

    Time frame: Up to 24 weeks

  11. Number of Participants With an AE Resulting in Death Through Week 24

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 24 weeks

07

Results

Posted Mar 21, 2023

Participant flow

Healthy HIV-uninfected male and female participants were enrolled at 9 study centers in 3 countries.

Participant flow — Overall Study
MilestoneIslatravir 60 mgIslatravir 120 mgPlacebo
Started979748
Completed829145
Not completed1563
Withdrew: Death100
Withdrew: Lost to follow-up432
Withdrew: Withdrawal by subject1011
Withdrew: Status not recorded020

Outcome measures

PrimaryNumber of Participants With ≥1 Adverse Event (AE) Through Week 36

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Adverse Event (AE) Through Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Adverse Event (AE) Through Week 36666336
PrimaryNumber of Participants Discontinuing From Study Therapy Due to AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing From Study Therapy Due to AE
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants Discontinuing From Study Therapy Due to AE110
PrimaryNumber of Participants Discontinuing From Study Therapy Due to ≥1 Drug-related AE

A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study therapy.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing From Study Therapy Due to ≥1 Drug-related AE
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants Discontinuing From Study Therapy Due to ≥1 Drug-related AE110
PrimaryNumber of Participants With ≥1 Drug-related AE Through Week 36

A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Drug-related AE Through Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Drug-related AE Through Week 3691412
PrimaryNumber of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36

An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36100
PrimaryNumber of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 36

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 36541
PrimaryNumber of Participants With ≥1 Drug-related SAE Through Week 36

An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Drug-related SAE Through Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Drug-related SAE Through Week 36000
PrimaryNumber of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 36

A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 36000
PrimaryNumber of Participants With an AE Resulting in Death Through Week 36

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With an AE Resulting in Death Through Week 36
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With an AE Resulting in Death Through Week 36000
SecondaryArea Under the Plasma Concentration-time Curve From Dosing to 672 Hours Postdose (AUC0-672) of Plasma ISL

The AUC0-672 of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

Time frame:
Day 1 and Day 140: predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.
Reported as:
Geometric mean · hr*umol/L
Area Under the Plasma Concentration-time Curve From Dosing to 672 Hours Postdose (AUC0-672) of Plasma ISL
hr*umol/LIslatravir 60 mgIslatravir 120 mgPlacebo
Day 17.88 ± 56.816.6 ± 50.5—
Day 14021.2 ± 140.337.6 ± 136.6—
SecondaryMaximum Plasma Concentration (Cmax) of ISL

The Cmax of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

Time frame:
Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.
Reported as:
Geometric mean · µmol/L
Maximum Plasma Concentration (Cmax) of ISL
µmol/LIslatravir 60 mgIslatravir 120 mgPlacebo
Day 10.387 ± 279.90.954 ± 186.2—
Day 1400.376 ± 597.70.792 ± 349.6—
SecondaryTrough Plasma Concentration (Ctrough) of ISL

The plasma Ctrough of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

Time frame:
Day 1 and Week 20: predose and 30-min postdose. Day 2: 24 hours post Day 1 dose. Weeks 1, 2, 3, 21, 22, 23 and 24: any time during the study visit. Weeks 4, 8, 12 and 16: predose.
Reported as:
Geometric mean · µmol/L
Trough Plasma Concentration (Ctrough) of ISL
µmol/LIslatravir 60 mgIslatravir 120 mgPlacebo
Day 10.000556 ± 36.60.00101 ± 37.0—
Day 1400.000809 ± 37.00.000124 ± 42.0—
SecondaryApparent Plasma Terminal Half-life (t1/2) of ISL

The plasma t1/2 of ISL after dosing on Day 140 is reported. Only ISL-treated participants are included in the PK analysis.

Time frame:
Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.
Reported as:
Geometric mean · Hours
Apparent Plasma Terminal Half-life (t1/2) of ISL
HoursIslatravir 60 mgIslatravir 120 mgPlacebo
Day 1NA ± NANA ± NA—
Day 140175 ± 16.2177 ± 19.8—
SecondaryNumber of Participants With ≥1 AE Through Week 24

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 AE Through Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 AE Through Week 24586032
SecondaryNumber of Participants With ≥1 Drug-related AE Through Week 24

A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Drug-related AE Through Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Drug-related AE Through Week 2491412
SecondaryNumber of Participants With ≥1 SAE Through Week 24

An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 SAE Through Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 SAE Through Week 24100
SecondaryNumber of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 24

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 24331
SecondaryNumber of Participants With ≥1 Drug-related SAE Through Week 24

An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Drug-related SAE Through Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Drug-related SAE Through Week 24000
SecondaryNumber of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 24

A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 24000
SecondaryNumber of Participants With an AE Resulting in Death Through Week 24

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With an AE Resulting in Death Through Week 24
ParticipantsIslatravir 60 mgIslatravir 120 mgPlacebo
Number of Participants With an AE Resulting in Death Through Week 24000

Adverse events

Collected over Up to 36 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Islatravir 60 mg1/97 (1%)1/97 (1%)24/97 (24.7%)
Islatravir 120 mg0/97 (0%)0/97 (0%)23/97 (23.7%)
Placebo0/48 (0%)0/48 (0%)16/48 (33.3%)
Most frequent serious events
Most frequent serious events
EventIslatravir 60 mgIslatravir 120 mgPlacebo
Intentional self-injuryPsychiatric disorders1/970/970/48
Loss of consciousnessNervous system disorders1/970/970/48
Most frequent other events
Most frequent other events
EventIslatravir 60 mgIslatravir 120 mgPlacebo
HeadacheNervous system disorders10/979/972/48
Abdominal painGastrointestinal disorders3/973/974/48
DiarrhoeaGastrointestinal disorders5/974/974/48
NauseaGastrointestinal disorders5/977/972/48
Upper respiratory tract infectionInfections and infestations4/974/973/48
Accidental overdoseInjury, poisoning and procedural complications0/971/973/48
Alanine aminotransferase increasedInvestigations2/970/973/48
DizzinessNervous system disorders2/970/973/48
Blood pressure increasedInvestigations1/975/970/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Islatravir 60 mgIslatravir 120 mgPlaceboTotal
Mean33.6 ± 9.933.2 ± 9.730.9 ± 7.932.9 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Islatravir 60 mgIslatravir 120 mgPlaceboTotal
Female666433163
Male31331579
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Islatravir 60 mgIslatravir 120 mgPlaceboTotal
Hispanic or Latino199836
Not Hispanic or Latino788840206
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Islatravir 60 mgIslatravir 120 mgPlaceboTotal
American Indian or Alaska Native0101
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American374816101
White554429128
More than one race53311
Unknown or Not Reported0000
08

Study locations

9 sites
  • Research Centers of America, LLC ( Site 0007)
    Hollywood, Florida 33024, United States
  • Johns Hopkins School of Medicine - Drug Development Unit ( Site 0002)
    Baltimore, Maryland 21287, United States
  • Celerion, Inc. ( Site 0006)
    Lincoln, Nebraska 68502, United States
  • Magee Womens Research Institute ( Site 0001)
    Pittsburgh, Pennsylvania 15213, United States
  • Hadassah Ein Karem Jerusalem ( Site 0016)
    Jerusalem, Jerusalem 9112001, Israel
  • Rambam Medical Center ( Site 0017)
    Haifa, 3109601, Israel
  • JOSHA Research ( Site 0015)
    Bloemfontein, Free State 9301, South Africa
  • Clinical HIV Research Unit CHRU ( Site 0014)
    Johannesburg, Gauteng 2092, South Africa
  • Emavundleni Vaccine Centre ( Site 0011)
    Cape Town, Western Cape 7750, South Africa
09

References and documents

Publications

  • Hillier SL, Bekker LG, Riddler SA, Hendrix CW, Badal-Faesen S, Macdonald P, Nair G, Lombaard J, Caraco Y, Peer A, Patel M, Vargo R, Homony B, Nedrow K, Evans B, Wickremasingha P, Zhou YP, Teal V, Hwang P, McMullan C, Kaufman KD, Robertson MN, Plank RM. Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1. J Infect Dis. 2025 Nov 14;232(5):1050-1060. doi: 10.1093/infdis/jiaf222. PubMed 40327547 ↗
  • Hendrix CW, Hillier SL, Bekker LG, Badal-Faesen S, Riddler SA, Marzinke MA, Fuchs EJ, Macdonald P, Edick S, Weld ED, Chavez-Eng CM, Evans B, Zang X, Vargo R, Homony B, Nedrow K, Plank RM, Robertson MN, Wickremasingha P, Patel M. Islatravir distribution in plasma, peripheral blood mononuclear cells, and mucosal tissues after monthly oral dosing. AIDS. 2026 Mar 6. doi: 10.1097/QAD.0000000000004477. Online ahead of print. PubMed 41789892 ↗
  • Pham M, Wickremasingha P, Vargo R, Patel M, Nedrow K, Homony B, Robertson MN, Plank RM. Brief Report: Exploratory Substudy of a Phase 2 Trial to Evaluate the Pharmacokinetic Effect of Once-Monthly Islatravir on Long-Acting Reversible Contraceptives. J Acquir Immune Defic Syndr. 2025 Aug 1;99(4):374-378. doi: 10.1097/QAI.0000000000003678. PubMed 40260892 ↗
  • Devanathan AS, Cottrell ML. Pharmacology of HIV Cure: Site of Action. Clin Pharmacol Ther. 2021 Apr;109(4):841-855. doi: 10.1002/cpt.2187. Epub 2021 Mar 5. PubMed 33540481 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Mar 2022, 29 months.

Results were first posted in Mar 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 1, 2019
StartActual
Sep 19, 2019
Primary completionActual
Mar 18, 2022
CompletionActual
Nov 24, 2022
Results first posted
Mar 21, 2023
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04003103
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Sep 19, 2019
Primary completion
Mar 18, 2022
Completion
Nov 24, 2022
Results posted
Mar 21, 2023
Last update
Jul 18, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Islatravir

Start the discussion